Generic Version of Hepatitis C Treatment can Improve Life Expectancy

Generic Version of Hepatitis C Treatment can Improve Life Expectancy

A new study reports that generic varieties of drug antivirals for treatment of Hepatitis C infections are cost-effective and can improve life expectancy with less complications.

Study was carried out by researcher Dr Rakesh Aggarwal from the Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow. Results of the study show that the generic versions of drugs such as Sofosbuvir, Ledipasvir, and Daclatasvir are cost-effective for Indian patients. Lifetime healthcare costs was observed to be reduced by around Rs 84, 000 per person while the life expectancy increased by eight years as compared to those who did not receiving any treatment. The generic drugs for HCV are available in India for about Rs. 19000 for each 12-week treatment course, as against Rs. 2.5 lakhs to Rs. 5 lakh for branded drugs sold in the US and Europe

The treatment with generic drugs became cost-effective within two years and cost-saving within 10 years of starting treatment. Cost saving was sooner for patients with the advanced disease across all age groups irrespective of the gender. The findings of the study encourage people suffering from Hepatitis C to opt for generic medicines to prevent complications and motivate doctors and policy makers to focus on the treatment of patients with advanced disease.

A total of 11 million people in India are suffering from chronic Hepatitis C infection, which is a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and other liver-related disorders. Hepatitis C infection have major economic implications due to expenditure on testing, treatment, and number of working hours.

According to Generic Drugs Market report Published by Coherent Market Insights, generic drugs yield the same therapeutic effect and are prescribed in the same dosing, with the same quality, and same the way of consumption and usage. Major advantage of generic drug is that they are cost-effective and affordable. The generic drugs for HCV are available in India for about Rs. 19000 for each 12-week treatment course, as against Rs. 2.5 lakhs to Rs. 5 lakh for branded drugs sold in the US and Europe

You may be interested

Amebiasis Treatment Market to Grow Like Never Before By 2026
Healthcare
Healthcare

Amebiasis Treatment Market to Grow Like Never Before By 2026

Albert R - August 18, 2018

Amebiasis Treatment Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market share,…

Gamma Probe Device Market to Grow Like Never Before By 2026
Healthcare
Healthcare

Gamma Probe Device Market to Grow Like Never Before By 2026

Albert R - August 18, 2018

Gamma Probe Device Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…

Metastatic Osteosarcoma Treatment Market – Latest Advancements
Healthcare
Healthcare

Metastatic Osteosarcoma Treatment Market – Latest Advancements

Albert R - August 18, 2018

Metastatic Osteosarcoma Treatment Market report 2018-2026 focuses on the major drivers and restraints for the key players. These research report also provides granular analysis of the market…

Most from this category